Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Disorder Clear all
Completed Phase 2 Interventional Results available

Atezolizumab Immunotherapy in Patients With Advanced NSCLC

NCT03102242
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years to 99 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 25, 2026, 5:42 AM EDT
Terminated Phase 1 Interventional

Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer

NCT02252796
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Hypofractionated Stereotactic Boost, Carboplatin, Paclitaxel, Image-guided IMRT
Radiation · Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Not applicable Interventional

The Six Minute Walk Test: Influence of Instruction on Results

NCT01789996
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
alternative six minute walk test, Standard six minute walk test
Procedure
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 90 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

NCT03520842
View directory record Official record
Conditions
KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Methotrexate, Pharmacokinetic Study, Regorafenib
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 25, 2026, 5:42 AM EDT
Not listed Not applicable Interventional

Informatics Framework for Pulmonary Rehabilitation

NCT03981783
View directory record Official record
Conditions
COPD
Interventions
Best available care (BAC), Telerehabilitation (TH)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Airway Obstruction in Infants With Lower Respiratory Infections

NCT00435994
View directory record Official record
Conditions
Bronchiolitis, Respiratory Syncytial Virus Infections
Interventions
Inhaled primatene will be given as a breathing treatment, Nasal Washing
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 2 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 25, 2026, 5:42 AM EDT
Not listed No phase listed Observational

Impact of Asthma Treatments on Daily Activities

NCT00350376
View directory record Official record
Conditions
Asthma, Allergies
Interventions
Not listed
Lead sponsor
Ovation Research Group
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,500 participants
Timeline
Started 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2006 · Synced Sep 25, 2026, 5:42 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin, Etoposide
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
20
States / cities
Daphne, Alabama • Hot Springs, Arkansas • Fort Myers, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 25, 2026, 5:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 25, 2026, 5:42 AM EDT
Terminated Not applicable Interventional Results available

Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study

NCT01608490
View directory record Official record
Conditions
Emphysema
Interventions
RePneu Lung Volume Reduction Coil System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
35 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 25, 2026, 5:42 AM EDT
Not listed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00104780
View directory record Official record
Conditions
Lung Cancer
Interventions
EP-2101, incomplete Freund's adjuvant
Biological
Lead sponsor
Epimmune
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
9
States / cities
Ocoee, Florida • Albany, New York • Durham, North Carolina + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 25, 2026, 5:42 AM EDT
Withdrawn Not applicable Interventional

Assessment of Occult Lung Stress During Lung Protective Mechanical Ventilation

NCT05675696
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Esophageal Catheter
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Not applicable Interventional

A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia

NCT00002103
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Leucovorin calcium
Drug
Lead sponsor
U.S. Bioscience
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
West Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

NCT03215927
View directory record Official record
Conditions
Myositis, Interstitial Lung Disease
Interventions
Abatacept, Placebo
Drug · Other
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 25, 2026, 5:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

NCT03148327
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab (MEDI 4736), Radiotherapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 25, 2026, 5:42 AM EDT
Suspended Phase 2 Interventional

Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

NCT07639242
View directory record Official record
Conditions
Lung Cancer, Lung Cancer (NSCLC), Locally Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
Interventions
Olomorasib, Pembrolizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Not applicable Interventional Results available

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle

NCT03004586
View directory record Official record
Conditions
Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Lung Cancer
Interventions
25-Gauge Needle, 22-Gauge Needle, Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)
Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

NCT03769090
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg
Combination Product · Drug
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
4 Years and older
Enrollment
3,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
170
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00305786
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT00658086
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, normal saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 25, 2026, 5:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

NCT04199741
View directory record Official record
Conditions
Small Cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
89Zr-DFO-SC16.56, SC16.56, Phase I, Cohort 2, SC16.56, Phase I, Cohort 3, SC16.56, Phase II
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 25, 2026, 5:42 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694
View directory record Official record
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Interventions
PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
61
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 5:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fiber Metabolism in Chronic Obstructive Pulmonary Disease

NCT04459156
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Aging
Interventions
Fiber Inulin, Placebo Maltodextrin
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 25, 2026, 5:42 AM EDT